Gilead Moves Beyond HIV with $2.1B Bet on Autoimmune T Cell Engager
By FieldPulse Editorial · March 24, 2026
Tags: Mergers & Acquisitions, Immunology, Pipeline
Gilead Sciences is acquiring Ouro Medicines for $2.1 billion to gain OM336, a first-in-class BCMAxCD3 T cell engager being developed for autoimmune diseases, signaling the company's intent to expand well beyond its HIV stronghold.
Gilead Sciences announced Monday it will acquire Ouro Medicines for $2.1 billion, securing rights to OM336 — also known as gamgertamig — a novel BCMAxCD3 T cell engager being developed for autoimmune diseases.
The transaction marks a deliberate push by Gilead to diversify its revenue base beyond HIV, where it has long dominated but where growth headroom is increasingly constrained.
OM336 works by engaging T cells to target BCMA-expressing cells implicated in autoimmune pathology — a mechanism more commonly associated with oncology applications, specifically multiple myeloma, now being explored in a different disease context.
The asset carries both FDA Orphan Drug designation and Fast Track status, reflecting the agency's recognition of its potential in conditions with limited treatment options.
Registrational studies are expected to begin in 2027.
The financial structure of the deal includes a notable cost-sharing arrangement: Galapagos, Gilead's longstanding research partner, will absorb 50% of the upfront acquisition cost as well as Ouro's operating assets.
That arrangement reflects the existing collaboration framework between the two companies and gives Galapagos meaningful exposure to what could become an important immunology asset.
For Gilead, the strategic logic is straightforward.
The company built its reputation and cash flow on transformative HIV therapies, but that franchise — while durable — has a ceiling.
Inflammation and autoimmune diseases represent one of the largest and fastest-growing segments in specialty pharma, and Gilead has signaled repeatedly that it wants a legitimate seat at that table.
The acquisition of Ouro is among the most concrete steps it has taken in that direction.
For reps and account managers in the immunology and rheumatology space, this acquisition is worth tracking.
If gamgertamig advances through registrational trials and reaches approval, Gilead would be entering a crowded but high-value market currently dominated by establis.